scholarly journals Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation

2016 ◽  
Vol 100 ◽  
pp. S19-S26 ◽  
Author(s):  
Federico Rea ◽  
Luciano Potena ◽  
Nizar Yonan ◽  
Florian Wagner ◽  
Fiorella Calabrese
1997 ◽  
Vol 17 (6) ◽  
pp. 489-494 ◽  
Author(s):  
Lionel Rostaing ◽  
Olivier Martinet ◽  
Jean-Marc Cisterne ◽  
Josette Icart ◽  
Marie-Hélène Chabannier ◽  
...  

1996 ◽  
Vol 4 (1) ◽  
pp. 4-13
Author(s):  
David D Yuh ◽  
Robert C Robbins ◽  
Bruce A Reitz

Heart and heart-lung transplantation have been established as effective treatments for a wide variety of end-stage cardiopulmonary diseases. Recent years have seen refinements in surgical techniques for cardiopulmonary replacement as well as the selection and postoperative care of thoracic transplant recipients. Despite substantial clinical progress, however, significant problems remain, particularly donor organ shortage, graft rejection, opportunistic infection, and limited organ preservation techniques. Basic and clinical research are currently addressing these problems. In this brief review, we provide an update of our experiences with heart and heart-lung transplantation in the West (particularly at Stanford University), an outline of the active issues in the field, and some thoughts about the development of thoracic transplantation in Asia.


2021 ◽  
pp. 107815522110604
Author(s):  
Kelly G Hawks ◽  
Amanda Fegley ◽  
Roy T Sabo ◽  
Catherine H Roberts ◽  
Amir A Toor

Introduction Cytomegalovirus (CMV) is one of the most common and clinically significant viral infections following allogeneic hematopoietic cell transplantation (HCT). Currently available options for CMV prophylaxis and treatment present challenges related to side effects and cost. Methods In this retrospective medical record review, the incidence of clinically significant CMV infection (CMV disease or reactivation requiring preemptive treatment) following allogeneic HCT was compared in patients receiving valacyclovir 1 g three times daily versus acyclovir 400 mg every 12 h for viral prophylaxis. Results Forty-five patients who received valacyclovir were matched based on propensity scoring to 35 patients who received acyclovir. All patients received reduced-intensity conditioning regimens containing anti-thymocyte globulin. Clinically significant CMV infection by day + 180 was lower in the valacyclovir group compared to the acyclovir group (18% vs. 57%, p = 0.0004). Patients receiving valacyclovir prophylaxis also had less severe infection evidenced by a reduction in CMV disease, lower peak CMV titers, delayed CMV reactivation, and less secondary neutropenia. Conclusion Prospective evaluation of valacyclovir 1 g three times daily for viral prophylaxis following allogeneic HCT is warranted. Due to valacyclovir's favorable toxicity profile and affordable cost, it has the potential to benefit patients on a broad scale as an option for CMV prophylaxis.


2022 ◽  
pp. 152692482110648
Author(s):  
Stefan Jobst ◽  
Jonas Schaefer ◽  
Christina Kleiser ◽  
Christiane Kugler

Introduction Acknowledging the evolved landscape in thoracic transplantation, professional employment becomes an important outcome measure to quantify the success of this costly procedure. Objective We aimed to assess rates of and characterize factors associated with professional employment in patients following thoracic transplantation, and create an evidence-base on the relationship between professional employment and relevant outcome parameters. Methods We systematically searched Medline, Cinahl, and GoogleScholar to identify studies published between 1998 and 2021 reporting on professional employment following heart and lung transplantation. Results Twenty-two studies from 11 countries with varying sample sizes (N = 27; 10 066) were included. Employment rates ranged from 19.7% to 69.4% for heart, and from 7.4% to 50.8% for lung transplant recipients. Most frequently reported positively associated factors with employment after transplant were younger age, higher education, and history of pretransplant employment. Longer duration of unemployment prior to transplantation and Medicaid coverage were the most frequently reported negatively associated factors. Relationships between professional employment and clinical outcomes included lower rates of acute and chronic rejection, less infection episodes, and better quality of life among working patients; one study reported a lower 5-year-mortality rate. Reasons not to work were “physical or mental health-related,” “employment-related,” “financial reasons,” and “lifestyle choices.” Discussion Substantial proportions of patients following thoracic transplantation are not professionally employed, potentially diminishing the success of transplantation on individual and societal levels. Considering adverse clinical outcomes in employed transplant recipients were low, more efforts are needed to identify modifiable factors for employment in these populations.


2000 ◽  
Vol 69 (Supplement) ◽  
pp. S238
Author(s):  
Bernard Kubak ◽  
Jon Kobashigawa ◽  
Jennifer Chuang ◽  
Robert Lee ◽  
Nishant Kumar ◽  
...  

2016 ◽  
Vol 1 (1) ◽  
Author(s):  
Gai Massimo ◽  
Clari Roberta ◽  
Dellepiane Sergio ◽  
Diena Davide ◽  
Manzione Ana ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document